SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Health care survey finds doctors, patients OK now, but fear for future Survey: Patients happy with service now, but afraid for future. Doctors fear future cost-pressures

Memorial Sloan Kettering, IBM looking at computerized skin cancer lesion identification Image mapping could guide the way to more accurate diagnoses

Philips acquires catheter-based imaging co., Volcano May help Philips break into EUR four billion image-guided therapy market

XR-29's lower dose CT requirements: Will iterative reconstruction play a role? As the industry inches toward new dose requirements, some implementation questions remain

Is Obamacare causing emergency room crowding? No, says new study The Affordable Care Act is not the cause of the problem. It comes from a primary care shortage

Could microwave tomography replace mammography? New experimental technique offers greater specificity with no radiation or patient discomfort

Hitachi partners with iVu for automated whole breast ultrasound

Fetal keepsake ultrasound videos have "potential for harm": FDA expert Time to find a new way to capture memories

Olympus' imaging technology for bladder biopsies gets FDA nod May allow for in-office treatment

Urban health - big cities, big challenges In July, the Carolinas HealthCare System Anson in Wadesboro, N.C., a town of about 5,800 people, opened the doors to its new facility and embarked on a bold experiment.

IBA spins off radiopharmaceutical division

by Brendon Nafziger , DOTmed News Associate Editor
New York private equity firm SK Capital Partners bought a controlling stake in Ion Beam Applications S.A.'s radiopharmaceutical division, which is being spun off into its own company, IBA announced Monday. Under the terms of the new deal, SK Capital will own 60 percent of the new business, called IBA Molecular Imaging, and IBA will retain a 40 percent stake.

The transaction, expected to close in the second quarter, is valued at 180 million euros ($229 million). IBA said it expects to net 100 million euros ($127 million) from the deal after debt adjustments, although the sale will result in "significant exceptional loss" for 2011 accounts as the transaction "does not value the IBA radiopharmaceutical business at the level previously booked in its consolidated statements," the company said in a statement.

Story Continues Below Advertisement

ENTERPRISE LEVEL INFORMATION SHARING - register for a demo

McKesson Enterprise Medical Imaging Solutions deliver what you need to stay connected and help ensure that patient information is in the right place at the right time and easily accessible by all members of the care team.



IBA's stock shot up to a six-month high after the announcement, Reuters reports, rising more than 31 percent and hitting 6.31 euros per share in trading Monday.

Although IBA owns 40 percent of the new company, it will reap 60 percent of the profits for drugs currently under development, in recognition of its past R&D investments, the Belgian company said. In the pipeline are imaging tracers to help diagnose kidney disease and Alzheimer's disease. The development costs of the in-the-works drugs now would be shared equally, the companies said.

Renaud Dehareng, the radiopharmaceutical group's former president, will helm the new entity as CEO, IBA said.

IBA's molecular imaging group employs 1,000 people, has 57 nuclear medicine sites in Europe, the United States and Asia, and runs a manufacturing facility in France. It generates about 175 million euros ($222 million) in yearly revenues, IBA said.

In a separate announcement, IBA said Olivier Legrain, the current chief strategic officer, would be promoted to chief operating officer in preparation for when he takes the reins from CEO Pierre Mottet, who's stepping down in May. However, Mottet will continue with the company as vice-chairman of the board.

IBA, which also makes cyclotrons for proton therapy treatments, is headquartered in Louvain-la-Neuve, Belgium.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Center
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED